文献速递呼吸危重症与机械通气

低氧性呼吸衰竭与ARDS的标准化管理:系统评价与荟萃分析

Standardized Management for Hypoxemic Respiratory Failure and ARDS: Systematic Review and Meta-analysis.
PubMed 文献 · Chest · 2020-07-03

标准化管理(护理方案、路径或集束化措施)与常规治疗相比,与死亡率相对降低23%相关(RR 0.77,95%CI 0.65-0.91;I²=70%;

要点

  • 标准化管理可相对降低低氧性呼吸衰竭患者死亡率23%(RR 0.77,95%CI 0.65-0.91)。
  • 针对ARDS患者的研究显示合并死亡率降低21%(RR 0.79,95%CI 0.71-0.88)。
  • 标准化管理与28天无呼吸机天数增加3.48天及潮气量降低1.80 mL/kg预测体重相关。

核心结论

  • 与常规治疗相比,低氧性呼吸衰竭和ARDS患者的标准化治疗与无呼吸机天数增加、更低潮气量通气及更低死亡率相关。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、EMBASE、Cochrane、CINAHL、Scopus和Web-of-Science(建库至2018年)。
  • 纳入随机临床试验或准实验研究,比较标准化治疗(护理方案、护理路径或集束化措施)与常规治疗在ICU机械通气成人低氧性呼吸衰竭或ARDS患者中的效果。

主要发现

  • 在针对ARDS患者的研究中(n=8),观察到合并死亡率降低21%(相对风险0.79;95%CI 0.71-0.88;I²=3.1%)。

临床怎么用

  • ICU应考虑使用标准化治疗(护理方案、护理路径或集束化措施)以改善低氧性呼吸衰竭和ARDS患者的诊疗过程与结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of hypoxemic respiratory failure (HRF) and ARDS is complex. Standardized management of HRF and ARDS may improve adherence to evidence-informed practice and improve outcomes. RESEARCH QUESTION: What is the effect of standardized treatment compared with usual care on survival of patients with HRF and ARDS? STUDY DESIGN AND METHODS: MEDLINE, EMBASE, Cochrane, CINAHL, Scopus, and Web-of-Science were searched (inception to 2018). Included studies were randomized clinical trials or quasi-experimental studies that examined the effect of standardized treatment (care-protocol, care-pathway, or bundle) compared with usual treatment among mechanically ventilated adult patients admitted to an ICU with HRF or ARDS. Study characteristics, pathway components, and patient outcomes were abstracted independently by two reviewers. RESULTS: From 15,932 unique citations, 14 studies were included in the systematic review (three randomized clinical trials and 11 quasi-experimental studies). Twelve studies (including 5,767 patients) were included in the meta-analysis. Standardized management of HRF was associated with a 23% relative reduction in mortality (relative risk, 0.77; 95% CI, 0.65-0.91; I2, 70%; P = .002). In studies targeting patients with ARDS (n = 8), a 21% pooled mortality reduction was observed (relative risk, 0.79; 95% CI, 0.71-0.88; I2, 3.1%). Standardized management was associated with increased 28-day ventilator-free days (weighted mean difference, 3.48 days; 95% CI, 2.43-4.54 days; P < .001). Standardized management was also associated with a reduction in tidal volume (weighted mean difference, -1.80 mL/kg predicted body weight; 95% CI, -2.80 to -0.80 mL/kg predicted body weight; P < .001). Meta-regression demonstrated that the reduction in mortality was associated with provision of lower tidal volume (P = .045). INTERPRETATION: When compared with usual treatment, standardized treatment of patients with HRF and ARDS is associated with increased ventilator-free days, lower tidal volume ventilation, and lower mortality. ICUs should consider the use of standardized treatment to improve the processes and outcomes of care for patients with HRF and ARDS. CLINICAL TRIAL REGISTRATION: PROSPERO; No.: CRD42019099921; URL: www.crd.york.ac.uk/prospero/.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Parhar KKS, Stelfox HT, Fiest KM, et al. Standardized Management for Hypoxemic Respiratory Failure and ARDS: Systematic Review and Meta-analysis. Chest. 2020. PMID: 32629038. doi:10.1016/j.chest.2020.05.611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。